Status:
COMPLETED
Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
Lead Sponsor:
Miller Orthopedic Specialists
Collaborating Sponsors:
CHI Health Mercy Hospital
Creighton University Medical Center
Conditions:
Osteoarthritis
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), rese...
Eligibility Criteria
Inclusion
- Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery
Exclusion
- Non-English speaking individuals
- Individuals with a history of deep vein thrombosis or pulmonary embolism within one year
- Individuals with a history of coagulopathy
- Heart stent within one year
- Pre-operative autologous blood donation
- Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis
- Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery
- Pre-operative creatinine greater than 1.5mg/dL
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT01873768
Start Date
January 1 2014
End Date
December 1 2015
Last Update
March 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miller Orthopedic Specialists
Council Bluffs, Iowa, United States, 51503